Bristol-Myers' Opdvio/Yervoy Combo Therapy Flunks In Head & Neck Cancer Trial

Bristol Myers Squibb & Co's BMY Phase 3 CheckMate -651 data evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) combo in head and neck cancer failed to primary endpoints of the trial.
The trial assessed Opdivo plus Yervoy combination to Extreme regimen (cetuximab, cisplatin/carboplatin, and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
The combination treatment did show a clear, positive trend towards overall survival (OS) in patients whose tumors express PD-L1.
The safety profile of Opdivo and Yervoy in this trial was consistent with previously reported studies in solid tumors.
The company will complete a full evaluation of the data and work with investigators to share the results with the scientific community.
Price Action: BMY shares are down 0.83% at $66.87 during the premarket session on the last check Friday.

Momentum42.60

Growth69.40

QualityNot Available

Value30.41

Short

Medium

Long